Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Company Overview

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Key Stats

• Today's Range: $1.57 to $1.68
• 50-Day Range: $1.35 to $1.94
• 52-Week Range: $1.03 to $6.51
• Volume: 151,199 shs
• Average Volume: 441,793 shs
• Market Capitalization: $50.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

Actinium Pharmaceuticals Stock Analysis - MarketRank™

Actinium Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 678th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Actinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Actinium Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Actinium Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Actinium Pharmaceuticals has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.30% of the outstanding shares of Actinium Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Actinium Pharmaceuticals has recently decreased by 22.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actinium Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Actinium Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.30% of the outstanding shares of Actinium Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Actinium Pharmaceuticals has recently decreased by 22.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Actinium Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Actinium Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

ATNM Stock Analysis - Frequently Asked Questions

How have ATNM shares performed this year?

Actinium Pharmaceuticals' stock was trading at $1.26 at the beginning of the year. Since then, ATNM stock has increased by 27.8% and is now trading at $1.61.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) posted its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02.

When did Actinium Pharmaceuticals' stock split?

Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Actinium Pharmaceuticals' major shareholders?

Top institutional shareholders of Actinium Pharmaceuticals include Y Intercept Hong Kong Ltd (0.21%).
View institutional ownership trends.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Fitbit (FIT) and OHR Pharmaceutical (OHRP).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ATNM
• Previous Symbol: NYSE:ATNM
• CIK: 1388320
• Web: N/A
• Phone: (646) 677-3870
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Actinium Pharmaceuticals: $4.00
• High Price Target: $5.00
• Low Price Target: $2.00
• Potential Upside/Downside: +148.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.82 million
• Net Margins: N/A
• Pretax Margin: -50,512.35%
• Return on Equity: -100.85%
• Return on Assets: -47.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 31,196,000
• Free Float: 29,324,000
• Market Cap: $50.23 million
• Optionable: Optionable
• Beta: -0.32